Canada Reviews Diabetic Ketoacidosis Risk With SGLT2 InhibitorsCanada Reviews Diabetic Ketoacidosis Risk With SGLT2 Inhibitors

Canada has become the latest country to investigate the association between SGLT2-inhibitor use in diabetes patients and the risk of euglycemic ketoacidosis. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news